Immunologic aspects of human sarcomas.
Forty-seven patients with mesenchymal sarcoma seen at the Mayo Clinic were tested for humoral and cellular immunologic responsiveness by means of a humoral cytotoxicity test, skin tests for delayed-type hypersensitivity, and lymphocyte transformation with concanavalin A, phytohemagglutinin, and pokeweed. Prospective follow-up of the clinical and laboratory results revealed that patients with low humoral cytotoxic indices, anergic skin test responses, or low lymphocyte transformation responsiveness tended to have the worst short-term clinical outlook.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001634:Bibliographies as Topic; D002648:Child; D003208:Concanavalin A / Q000494:pharmacology; D003601:Cytotoxicity Tests, Immunologic; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed; D007109:Immunity; D007111:Immunity, Cellular; D037102:Lectins / Q000494:pharmacology; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D008934:Mitogens / Q000494:pharmacology; D011379:Prognosis; D012509:Sarcoma / Q000276:immunology*; D012882:Skin Tests; D012983:Soft Tissue Neoplasms / Q000276:immunology
D037102:Lectins; D008934:Mitogens; D003208:Concanavalin A